Positive Coomb's test in newborns; causes and clinical consequences Summary of cases diagnosed in the Blood Bank in the years 2005 to 2012;Mótefni bundin vio rauokorn nýbura; orsakir og klínískar afleioingar Tilfelli greind í Blóobankanum 2005-2012

Laeknabladid

Volumn 102, Issue 7-8, 2016, Pages 326-331

  Kristinsdóttir, Thórdis ^a   Kjartansson, Sveinn ^b   Hardardottir, Hildur ^a,c   Jonsson, Thorbjörn ^c   Halldorsdottir, Anna Margret ^c  

^a UNIVERSITY OF ICELAND   (Iceland)

^b Children's Hospital of Landspítali   (Iceland)

^c Landspítali ^*  (Iceland)

Author keywords

ABO blood group mismatch; Coombs test; Direct Antiglobulin Test (DAT); Exchange transfusion; Hemolytic disease of the fetus and newborn (HDFN); Neonatal jaundice; Red cell alloantibodies

Indexed keywords

ALLOANTIBODY; BIOLOGICAL MARKER; BLOOD GROUP ABO SYSTEM;

BLOOD; BLOOD BANK; BLOOD GROUP ABO SYSTEM; BLOOD GROUP INCOMPATIBILITY; BLOOD TRANSFUSION; COOMBS TEST; ERYTHROBLASTOSIS, FETAL; ERYTHROCYTE; FETUS BLOOD; HISTOCOMPATIBILITY TEST; HUMAN; IMMUNOLOGY; JAUNDICE, NEONATAL; NEWBORN; NEWBORN SCREENING; PHOTOTHERAPY; PREDICTIVE VALUE; PROCEDURES; PROGNOSIS; TIME FACTOR;

ABO BLOOD-GROUP SYSTEM; BIOMARKERS; BLOOD BANKS; BLOOD GROUP INCOMPATIBILITY; BLOOD TRANSFUSION; COOMBS TEST; ERYTHROBLASTOSIS, FETAL; ERYTHROCYTES; FETAL BLOOD; HISTOCOMPATIBILITY TESTING; HUMANS; INFANT, NEWBORN; ISOANTIBODIES; JAUNDICE, NEONATAL; NEONATAL SCREENING; PHOTOTHERAPY; PREDICTIVE VALUE OF TESTS; PROGNOSIS; TIME FACTORS;

EID: 84978198671     PISSN: 00237213     EISSN: 16704959     Source Type: Journal    
DOI: 10.17992/lbl.2016.0708.90     Document Type: Review

References (27)

1. Poole J, Daniels G. Blood group antibodies and their significance in transfusion medicine. Transfus Med Rev 2007; 21: 58-71.
2. Harmening DM. Modern Blood Banking & Transfusion Practices. 5th ed. F.A. Davis Company, Fíladelfíu, Bandaríkjunum 2005.
3. Chen JY, Ling UP. Prediction of the development of neonatal hyperbilirubinemia in ABO incompatibility. Zhonghua Yi Xue Za Zhi (Taipei) 1994; 53: 13-8.
4. Petrides M, Stack G, Cooling L, Maes LY. Practical Guide to Transfusion Medicine. 2nd ed. AABB Pres, Bethesda, Maryland 2007.
5. Murray NA, Roberts IA. Haemolytic disease of the newborn. Arch Dis Child Fetal Neonatal Ed 2007; 92: F83-F88.
6. Bowman J. Thirty-five years of Rh prophylaxis. Transfusion 2003; 43: 1661-6.
7. Roberts IA. The changing face of haemolytic disease of the newborn. Early Hum Dev 2008; 84: 515-23.
8. Geifman-Holtzman O, Wojtowycz M, Kosmas E, Artal R. Female alloimmunization with antibodies known to cause hemolytic disease. Obstet Gynecol 1997; 89: 272-5.
9. Hellman-Erlingsson S. Greining blódflokkamótefna hjá vanfærum konum og mædrum á Íslandi 1970-1984. Læknabladid 1986; 72: 321-9.
10. Nordvall M, Dziegel M, Hegaard HK, Bidstrup M, Jonsbo F, Christensen B, et al. Red blood cell antibodies in pregnancy and their clinical consequences: synergistic effects of multiple specificities. Transfusion 2009; 9: 2070-5.
11. Dinesh D. Review of positive direct antiglobulin tests found on cord blood sampling. J Paediatr Child Health 2005; 41: 504-7.
12. Coombs RRA, Mourant AE, Race RR. In-vivo isosensitisation of red cells in babies with hæmolytic disease. Lancet 1946; 247: 264-6.
13. Pediatrics A.A.o. Clinical practice guideline: management of hyperbilirubinemia in the newborn infant 35 or more weeks of gestation. Pediatrics 2004; 114: 297-316.
14. Herschel M, Karrison T, Wen M, Caldarelli L, Baron B. Evaluation of the direct antiglobulin (Coombs') test for identifying newborns at risk for hemolysis as determined by end-tidal carbon monoxide concentration (ETCOc); and comparison of the Coombs' test with ETCOc for detecting significant jaundice. J Perinatol 2002; 22: 341-7.
15. Cortey A, Brossard Y. [Adverse effects and patient information]. J Gynecol Obstet Biol Reprod (Paris) 2006; 35(1 Suppl): 1S112-1S118.
16. Madan A, Huntsinger K, Burgos A, Benitz WE. Readmission for newborn jaundice: the value of the Coombs' test in predicting the need for phototherapy. Clin Pediatr 2004; 43: 63-8.
17. Dillon A, Chaudhari T, Crispin P, Shadbolt B, Kent A. Has anti-D prophylaxis increased the rate of positive direct antiglobulin test results and can the direct antiglobulin test predict need for phototherapy in Rh/ABO incompatibility? J Paediatr Child Health 2011; 47: 40-3.
18. Moise KJ. Fetal anemia due to non-Rhesus-D red-cell alloimmunization. Sem Fetal Neonatal Med 2008; 13: 207-14.
19. McKenna DS, Nagaraja HN, O'Shaughnessy R. Management of pregnancies complicated by anti-Kell isoimmunization. Obstet Gynecol 1999; 93: 667-73.
20. Kaplan M, Hammerman C, Vreman HJ, Wong RJ, Stevenson DK. Hemolysis and hyperbilirubinemia in antiglobulin positive, direct ABO blood group heterospecific neonates. J Pediatr 2010; 157: 772-7.
21. Daniels G, Poole J, De Silva M, Callaghan T, MacLennan S, Smith N. The clinical significance of blood group antibodies. Transfus Med 2002; 12: 287-95.
22. American Academy of Pediatrics Subcommittee on Hyperbilirubinemia. Management of hyperbilirubinemia in the newborn infant 35 or more weeks of gestation. Pediatrics 2004; 114: 297-316.
23. Kaplan M, Na'amad M, Kenan A, Rudensky B, Hammerman C, Vreman HJ, et al. Failure to predict hemolysis and hyperbilirubinemia by IgG Subclass in blood group A or B infants born to group O mothers. Pediatr 2009; 123: e132-e137.
24. Sgro M, Campbell D, Shah V. Incidence and causes of severe neonatal hyperbilirubinemia in Canada. CMAJ 2006; 175: 587-90.
25. Wainer S, Rabi J, Lyon M. Coombs' testing and neonatal hyperbilirubinemia. CMAJ 2007; 176: 972-3; author reply 973.
26. Elalfy MS, Elbarbary NS, Abaza HW. Early intravenous immunoglobin (two-dose regimen) in the management of severe Rh hemolytic disease of newborn-a prospective randomized controlled trial. Eur J Pediatr 2011; 170: 461-7.
27. Smits-Wintjens VE, Walther FJ, Rath ME, Lindenburg IT, te Pas AB, Kramer CM, et al. Intravenous immunoglobulin in neonates with rhesus hemolytic disease: a randomized controlled trial. Pediatr 2011; 127: 680-6.